CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback